Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norovirus bivalent vaccine in children aged 6 months to 13 years
NCT05916326Phase 3Completed
- Sponsor
- Serum Institute of India
- Start
- Jun 2023
- Primary completion
- Jul 2025
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant bivalent norovirus vaccine in norovirus infection, gastroenteritis, sponsored by Serum Institute of India. Started Jun 2023; status: completed.
02
Drugs
recombinant bivalent norovirus vaccine
03
Conditions
norovirus infectiongastroenteritis
Beyond the preview
Go deeper on NCT05916326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05916326.